An evaluation of the drug interaction potential of pazopanib, an oral vascular endothelial growth factor receptor tyrosine kinase inhibitor, using a modified cooperstown 51 cocktail in patients with advanced solid tumors

Clinical Pharmacology and Therapeutics

Volumn 88, Issue 5, 2010, Pages 652-659

  Goh, B C ^a   Reddy, N J ^b   Dandamudi, U B ^b   Laubscher, K H ^c   Peckham, T ^c   Hodge, J P ^c   Suttle, A B ^c   Arumugham, T ^c   Xu, Y ^c   Xu, C F ^c   Lager, J ^c   Dar, M M ^c   Lewis, L D ^b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b NORRIS COTTON CANCER CENTER   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAFFEINE; CYTOCHROME P450 1A2; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A; DEXTROMETHORPHAN; MIDAZOLAM; OMEPRAZOLE; PAZOPANIB; UNCLASSIFIED DRUG; VITAMIN K GROUP; VOTRIENT; WARFARIN; ANGIOGENESIS INHIBITOR; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; ISOENZYME; MOLECULAR PROBE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE; SULFONAMIDE; VASCULOTROPIN RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANEMIA; ANOREXIA; ANTIANGIOGENIC THERAPY; AREA UNDER THE CURVE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER PATIENT; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; DEPIGMENTATION; DRUG BLOOD LEVEL; DRUG ERUPTION; ENZYME INHIBITION; FATIGUE; FEMALE; HAIR COLOR; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERKALEMIA; HYPERTENSION; HYPONATREMIA; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; PANCREATITIS; PHARMACOGENETICS; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; SOLID TUMOR; ANTAGONISTS AND INHIBITORS; COMPARATIVE STUDY; DRUG INTERACTION; ENZYME SPECIFICITY; ENZYMOLOGY; GENETIC POLYMORPHISM; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; MOLECULAR PROBE; MULTICENTER STUDY; NEOPLASMS; ORAL DRUG ADMINISTRATION; PATHOLOGY; PHENOTYPE; SINGAPORE; TREATMENT OUTCOME; UNITED STATES;

ADMINISTRATION, ORAL; AGED; ANGIOGENESIS INHIBITORS; CYTOCHROME P-450 ENZYME SYSTEM; DRUG INTERACTIONS; FEMALE; GENOTYPE; HUMANS; ISOENZYMES; MALE; MIDDLE AGED; MOLECULAR PROBES; NEOPLASMS; NEW HAMPSHIRE; PHENOTYPE; POLYMORPHISM, GENETIC; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SINGAPORE; SUBSTRATE SPECIFICITY; SULFONAMIDES; TREATMENT OUTCOME; CYTOCHROME P-450 ENZYME INHIBITORS;

EID: 77958498524     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1038/clpt.2010.158     Document Type: Article

References (21)

1. GlaxoSmithKline. Votrient™ (pazopanib) tablets prescribing information (2009).
2. Harris, P.A. et al. Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl) methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J. Med. Chem. 51, 4632-4640 (2008).
3. Hurwitz, H.I. et al. Phase I trial of pazopanib in patients with advanced cancer. Clin. Cancer Res. 15, 4220-4227 (2009).
4. Friedlander, M. et al. Pazopanib (GW786034) is active in women with advanced epithelial ovarian, fallopian tube and peritoneal cancers: initial results of a phase II study. 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25 (suppl.), 289s, abstract 5561 (2007).
5. Hutson, T.E. et al. Pazopanib (GW786034) is active in metastatic renal cell carcinoma (RCC): interim results of a phase II randomized discontinuation trial (RDT). 2007 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 25 (suppl.), 242s, abstract 5031 (2007).
6. Sleijfer, S. et al. Phase II study of pazopanib (GW786034) in patients (pts) with relapsed or refractory soft tissue sarcoma (STS): EORTC 62043. 2007 ASCO Annual Meeting Proceedings Part 1. J. Clin. Oncol. 25 (suppl.), 552s, abstract 10031 (2007).
7. Chainuvati, S. et al. Combined phenotypic assessment of cytochrome p450 1A2, 2C9, 2C19, 2D6, and 3A, N-acetyltransferase-2, and xanthine oxidase activities with the "Cooperstown 5+1 cocktail". Clin. Pharmacol. Ther. 74, 437-447 (2003).
8. Streetman, D.S. et al. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail". Clin. Pharmacol. Ther. 68, 375-383 (2000).
9. Myrand, S.P. et al. Pharmacokinetics/genotype associations for major cytochrome P450 enzymes in native and frst-and third-generation Japanese populations: comparison with Korean, Chinese, and Caucasian populations. Clin. Pharmacol. Ther. 84, 347-361 (2008).
10. Helsby, N.A. et al. CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype. Br. J. Cancer 99, 1251-1255 (2008).
11. Rivory, L.P., Slaviero, K.A. & Clarke, S.J. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br. J. Cancer 87, 277-280 (2002).
12. Huang, S.M. et al. New era in drug interaction evaluation: US Food and Drug Administration update on CYP enzymes, transporters, and the guidance process. J. Clin. Pharmacol. 48, 662-670 (2008).
13. Tan, A.R. et al. Phase I study of the safety, tolerability, and pharmacokinetics (PK) of weekly paclitaxel administered in combination with pazopanib (GW786034). J. Clin. Oncol. 26 (May 20 suppl.) 1662, abstract 3552 (2008).
14. GlaxoSmithKline. Tykerb (lapatinib ditosylate) prescribing information (2010).
15. Dejonge, M. et al. A phase I, open-label study of the safety and pharmacokinetics (PK) of pazopanib (P) and lapatinib (L) administered concurrently. 2006 ASCO Annual Meeting Proceedings Part I. J. Clin. Oncol. 24 (suppl.), 142s, abstract 3088 (2006).
16. Lessard, E. et al. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans. J. Clin. Psychopharmacol. 21, 175-184 (2001).
17. Alfaro, C.L., Lam, Y.W., Simpson, J. & Ereshefsky, L. CYP2D6 inhibition by fuoxetine, paroxetine, sertraline, and venlafaxine in a crossover study: intraindividual variability and plasma concentration correlations. J. Clin. Pharmacol. 40, 58-66 (2000).
18. Johnson, B.M. et al. Evaluation of the drug interaction potential of aplaviroc, a novel human immunodefciency virus entry inhibitor, using a modifed cooperstown 5 + 1 cocktail. J. Clin. Pharmacol. 46, 577-587 (2006).
19. Williams, J.A. et al. PhRMA white paper on ADME pharmacogenomics. J. Clin. Pharmacol. 48, 849-889 (2008).
20. Home Page of the Human Cytochrome P450 (CYP) Allele Nomenclature Committee (2008).
21. National Cancer Institute Common Terminology Criteria for Adverse Events, version 3 .